P
PHIO PHARMACEUTICALS CORP
NASDAQ: PHIO (Phio Pharmaceuticals Corp.)
Kemas kini terakhir: 1 jam lalu0.985
-0.02 (-1.50%)
| Penutupan Terdahulu | 1.00 |
| Jumlah Dagangan | 54,214 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.310 |
| Harga / Jualan (P/S) | 48.01 |
| Harga / Buku (P/B) | 0.940 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -9.02 |
| Nisbah Semasa (MRQ) | 10.58 |
| Aliran Tunai Operasi (OCF TTM) | -6.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.01 M |
| Pulangan Atas Aset (ROA TTM) | -43.43% |
| Pulangan Atas Ekuiti (ROE TTM) | -76.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Phio Pharmaceuticals Corp. | Bercampur | Bercampur |
AISkor Stockmoo
-1.4
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 4.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.38 |
|
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.40% |
| % Dimiliki oleh Institusi | 15.77% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BITTERMAN ROBERT J | 1.00 | - | 2,000 | 2,000 |
| BRADFORD PATRICIA A | 1.02 | - | 6,500 | 6,630 |
| Jumlah Keseluruhan Kuantiti Bersih | 8,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 8,630 | |||
| Purata Pembelian Keseluruhan ($) | 1.01 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BRADFORD PATRICIA A | Pengarah | 24 Sep 2026 | Beli (+) | 6,500 | 1.02 | 6,630 |
| BITTERMAN ROBERT J | Pegawai | 22 Sep 2026 | Beli (+) | 2,000 | 1.00 | 2,000 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |